B. Schackman

PROFILE

Homepage
No homepage is listed.
ORCID
No ORCID is listed.
Affiliations
No affiliations are listed.
Aliases
B.r. Schackman, Bruce R Schackman, B. Schackman, Bruce Schackman, Bruce R. Schackman
Publication record
231 papers · 9,341 citations · H-index 47

PAPERS

Keep it up! 3.0: Study protocol for a type III hybrid implementation-effectiveness cluster-randomized trial.
202311 citationsauthor #11
The effects of COVID-19 on New York State’s Drug User Health Hubs and syringe service programs: a qualitative study
20239 citationsauthor #4
Cost-effectiveness of Increasing Buprenorphine Treatment Initiation, Duration, and Capacity Among Individuals Who Use Opioids
20237 citationsauthor #9
Cost-Effectiveness of Annual Prostate MRI and Potential MRI-Guided Biopsy After Prostate-Specific Antigen Test Results
202315 citationsauthor #8
Economic benefits of substance use disorder treatment: A systematic literature review of economic evaluation studies from 2003 to 2021.
202310 citationsauthor #3
Economic Cost of the HealthCall Smartphone Intervention to Reduce Heavy Alcohol Drinking in Adults with HIV.
20230 citationsauthor #8
Racial/ethnic differences in receipt of naloxone distributed by opioid overdose prevention programs in New York City
202312 citationsauthor #9
Racial/Ethnic differences in receipt of naloxone distributed by opioid overdose prevention programs in New York City
20233 citationsauthor #9
Changes to opioid overdose deaths and community naloxone access among Black, Hispanic and White people from 2016 to 2021 with the onset of the COVID-19 pandemic: An interrupted time-series analysis in Massachusetts, USA.
202319 citationsauthor #11
Responding to a surge in overdose deaths: perspectives from US syringe services programs
202227 citationsauthor #13
Harm reduction and health services provided by syringe services programs in 2019 and subsequent impact of COVID-19 on services in 2020
202243 citationsauthor #9
Evaluating equity in community-based naloxone access among racial/ethnic groups in Massachusetts.
202240 citationsauthor #10
Availability of and Obstacles to Providing COVID-19 Vaccinations at Syringe Services Programs in the United States, 2021
20226 citationsauthor #11
Barriers to engaging people who use drugs in harm reduction services during the COVID-19 pandemic: A mixed methods study of syringe services program perspectives
202218 citationsauthor #13
Comparing Projected Fatal Overdose Outcomes and Costs of Strategies to Expand Community-Based Distribution of Naloxone in Rhode Island
202218 citationsauthor #11
Syringe Service Program Perspectives on Barriers, Readiness, and Programmatic Needs to Support Rollout of the COVID-19 Vaccine
20226 citationsauthor #13
Cost of Hepatitis C care facilitation for HIV/Hepatitis C Co-infected people who use drugs.
20222 citationsauthor #13
Correction: M2HepPrEP: study protocol for a multi-site multi-setting randomized controlled trial of integrated HIV prevention and HCV care for PWID
20221 citationsauthor #4
Targeting community-based naloxone distribution using opioid overdose death rates: A descriptive analysis of naloxone rescue kits and opioid overdose deaths in Massachusetts and Rhode Island.
202123 citationsauthor #10
Hepatitis C Treatment by Nonspecialist Providers in the Direct-acting Antiviral Era
20216 citationsauthor #4
Community-based Naloxone Coverage Equity for the Prevention of Opioid Overdose Fatalities in Racial/Ethnic Minority Communities in Massachusetts and Rhode Island.
202115 citationsauthor #12
Improving health equity and ending the HIV epidemic in the USA: a distributional cost-effectiveness analysis in six cities.
202114 citationsauthor #18
Cost-Effectiveness Implications of Increasing the Efficiency of the Extended-Release Naltrexone Induction Process for the Treatment of Opioid Use Disorder: A Secondary Analysis.
20213 citationsauthor #11
Costs of Opioid Overdose Education and Naloxone Distribution in New York City
202111 citationsauthor #9
Economic Evaluations of Pharmacologic Treatment for Opioid Use Disorder: A Systematic Literature Review.
202127 citationsauthor #3
Human Immunodeficiency Virus transmission by HIV Risk Group and Along the HIV Care Continuum: A Contrast of 6 US Cities
20216 citationsauthor #15
Robust Prescription Monitoring Programs and Abrupt Discontinuation of Long-term Opioid Use.
20217 citationsauthor #9
Projected Estimates of Opioid Mortality After Community-Level Interventions
202157 citationsauthor #12
The Experience of Implementing a Low-Threshold Buprenorphine Treatment Program in a Non-Urban Medical Practice
20211 citationsauthor #5
A Harm Reduction Approach to Treating Opioid Use Disorder in an Independent Primary Care Practice: a Qualitative Study
202135 citationsauthor #5
Ending the HIV epidemic in the USA: an economic modelling study in six cities.
202056 citationsauthor #15
PDG65 OPIOID USE DISORDER AND HEALTH-RELATED QUALITY OF LIFE
20200 citationsauthor #10
Comparison of Rates of Overdose and Hospitalization After Initiation of Medication for Opioid Use Disorder in the Inpatient vs Outpatient Setting
202030 citationsauthor #6
Community viral load and hepatitis C virus infection: Community viral load measures to aid public health treatment efforts and program evaluation.
20206 citationsauthor #5
'Ending the Epidemic' will not happen without addressing racial/ethnic disparities in the US HIV epidemic.
202027 citationsauthor #16
Impact of Removing Medicaid Fee-for-Service Hepatitis C Virus (HCV) Treatment Restrictions on HCV Provider Experience with Medicaid Managed Care Organizations in New York City
20207 citationsauthor #6
Hepatitis C Virus Incidence in a Cohort in Medication-Assisted Treatment for Opioid Use Disorder in New York City.
202012 citationsauthor #4
State Policies for Prescription Drug Monitoring Programs and Adverse Opioid-related Hospital Events
20208 citationsauthor #4
COVID-19 Could Change the Way We Respond to the Opioid Crisis-for the Better.
202020 citationsauthor #3
Title: Keep It Up! 3.0: Study Protocol for a Type III Hybrid Implementation-Effectiveness Cluster-Randomized Trial
20201 citationsauthor #9
The potential epidemiological impact of COVID-19 on the HIV/AIDS epidemic and the cost-effectiveness of linked, opt-out HIV testing: A modeling study in six US cities
202031 citationsauthor #13
Evaluation of Alcohol Taxes as a Public Health Opportunity to Reduce Liver Transplant Listings for Alcohol-Related Liver Disease.
20204 citationsauthor #7
Can the 'Ending the HIV Epidemic' initiative transition the US towards HIV/AIDS epidemic control?
20204 citationsauthor #7
Harmonizing healthcare and other resource measures for evaluating economic costs in substance use disorder research
20204 citationsauthor #10
Economic evaluation in the National Drug Abuse Treatment Clinical Trials Network: Past, present, and future.
20208 citationsauthor #5
Dissemination Science to Advance the Use of Simulation Modeling: Our Obligation Moving Forward
20206 citationsauthor #11
Hepatitis C Virus (HCV) Care Continuum Outcomes and HCV Community Viral Loads Among Patients in an Opioid Treatment Program.
20207 citationsauthor #3
The Value and Challenge of Frequent HIV Testing Among Young Men Who Have Sex With Men in the United States.
20202 citationsauthor #1
Bundling Rapid Human Immunodeficiency Virus and Hepatitis C Virus Testing to Increase Receipt of Test Results
202010 citationsauthor #7
The HEALing (Helping to End Addiction Long-term SM) Communities Study: Protocol for a cluster randomized trial at the community level to reduce opioid overdose deaths through implementation of an integrated set of evidence-based practices
2020131 citationsauthor #82
Ending the HIV Epidemic Among Persons Who Inject Drugs: A Cost-Effectiveness Analysis in Six US Cities.
202010 citationsauthor #14
Health-related quality of life and opioid use disorder pharmacotherapy: A secondary analysis of a clinical trial.
202018 citationsauthor #10
Addressing Barriers to On-site HIV and HCV Testing Services in Methadone Maintenance Treatment Programs in the United States: Findings From a National Multisite Qualitative Study.
20209 citationsauthor #3
Structural Design and Data Requirements for Simulation Modelling in HIV/AIDS: A Narrative Review
20199 citationsauthor #6
Overdose following initiation of naltrexone and buprenorphine medication treatment for opioid use disorder in a United States commercially insured cohort.
2019141 citationsauthor #2
Strengthening partnerships between substance use researchers and policy makers to take advantage of a window of opportunity
201913 citationsauthor #9
Cost-effectiveness of a Medical Care Coordination Program for People With HIV in Los Angeles County
20197 citationsauthor #4
PMH20 COST-EFFECTIVENESS OF INCREASING THE EFFICIENCY OF THE DETOXIFICATION PROCESS PRIOR TO INITIATION OF EXTENDED-RELEASE NALTREXONE FOR THE TREATMENT OF OPIOID USE DISORDER
20190 citationsauthor #9
M2HepPrEP: study protocol for a multi-site multi-setting randomized controlled trial of integrated HIV prevention and HCV care for PWID
20197 citationsauthor #4
Spatial distribution and characteristics of HIV clusters in Ethiopia
201910 citationsauthor #3
Hepatitis C Treatment Uptake by New Prescribers After the Introduction of Direct Acting Antivirals
20193 citationsauthor #3
Development and Calibration of a Dynamic HIV Transmission Model for 6 US Cities
201935 citationsauthor #6
Prescribing decisions at buprenorphine treatment initiation: Do they matter for treatment discontinuation and adverse opioid-related events?
201942 citationsauthor #4
Study protocol for a pragmatic trial of the Consult for Addiction Treatment and Care in Hospitals (CATCH) model for engaging patients in opioid use disorder treatment
201934 citationsauthor #11
THU-421-Lower alcohol taxes are associated with increased liver transplant listing
20190 citationsauthor #6
Cost-effectiveness of HCV Treatment Models for People Who Inject Drugs in Opioid Agonist Treatment Programs.
201916 citationsauthor #2
Will converting naloxone to over‐the‐counter status increase pharmacy sales?
201929 citationsauthor #4
The FANMI (“my FAMILY” in Creole) study to evaluate community-based cohort care for adolescent and young women living with HIV in Haiti: protocol for a randomized controlled trial
20198 citationsauthor #15
PDG72 DETERMINANTS OF AN EFFICIENT MODEL OF EXTENDED-RELEASE NALTREXONE INITIATION FOR THE TREATMENT OF OPIOID USE DISORDER
20190 citationsauthor #9
Cost-effectiveness of integrating buprenorphine-naloxone treatment for opioid use disorder into clinical care for persons with HIV/hepatitis C co-infection who inject opioids.
201932 citationsauthor #4
Developing a dynamic HIV transmission model for 6 U.S. cities: An evidence synthesis
201936 citationsauthor #14
Commentary: The value of using community simulation modeling to achieve HCV elimination targets in people who inject drugs
20190 citationsauthor #1
Ending the epidemic in America will not happen if the status quo continues: modeled projections for HIV incidence in 6 US cities.
201915 citationsauthor #13
Strategies for Improving Hepatitis C Treatment Access in the United States: State Officials Address High Drug Prices, Stigma, and Building Treatment Capacity
201916 citationsauthor #4
Commentary on Barbosa et al. (2019): The value of using community simulation modeling to achieve HCV elimination targets in people who inject drugs.
20191 citationsauthor #1
The impact of localized implementation: determining the cost-effectiveness of HIV prevention and care interventions across six United States cities.
201935 citationsauthor #13
Estimated impact of supervised injection facilities on overdose fatalities and healthcare costs in New York City.
201933 citationsauthor #10
Why Maximizing Quality-Adjusted Life Years, rather than Reducing HIV Incidence, Must Remain Our Objective in Addressing the HIV/AIDS Epidemic
20199 citationsauthor #9
Cost of an HIV Medical Care Coordination Program in Los Angeles County.
20192 citationsauthor #1
Improving HIV service delivery for people who inject drugs in Kazakhstan: study protocol for the Bridge stepped-wedge trial
20199 citationsauthor #11
A Cost Reimbursement Model for Hepatitis C Treatment Care Coordination
20199 citationsauthor #13
862. Spatial Distribution of HIV Transmission in Ethiopia and Characteristics of HIV Clusters
20180 citationsauthor #3
Su1861 - Rising Trends in Opioid use Disorder-Related Diagnoses Among Hospitalized Inflammatory Bowel Disease Patients
20180 citationsauthor #6
2216. Hepatitis C Treatment Wanted Yet Not Received: Barriers to Receiving HCV Treatment Among People Who Inject Drugs
20181 citationsauthor #6
State Medicaid Hepatitis C Treatment Eligibility Criteria and Use of Direct-Acting Antivirals
201822 citationsauthor #3
First Opioid Prescription and Subsequent High-Risk Opioid Use: a National Study of Privately Insured and Medicare Advantage Adults
201825 citationsauthor #6
Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population.
2018295 citationsauthor #2
The Impact of Opioid Epidemic Trends on Hospitalised Inflammatory Bowel Disease Patients
201836 citationsauthor #7
Treating and Preventing HIV with Generic Drugs - Barriers in the United States.
201817 citationsauthor #2
Rationale, design, and methodology of a trial evaluating three models of care for HCV treatment among injection drug users on opioid agonist therapy
201823 citationsauthor #6
Cost-Effectiveness of BuprenorphineNaloxone Versus Extended-Release Naltrexone to Prevent Opioid Relapse
201858 citationsauthor #10
Availability of HIV and HCV On-Site Testing and Treatment at Syringe Service Programs in the United States.
201826 citationsauthor #6
Cost-effectiveness of hepatitis C screening and treatment linkage intervention in US methadone maintenance treatment programs.
201854 citationsauthor #1
Criminal justice measures for economic data harmonization in substance use disorder research
20189 citationsauthor #13
Findings Prevalence and Attitudes Regarding Marijuana Use Among Adolescents Over the Past
20181 citationsauthor #3
Telementoring of primary care providers delivering hepatitis C treatment in New York City: Results from Project INSPIRE
201810 citationsauthor #11
Implementation of A Nationwide Health Economic Consultation Service to Assist Substance Use Researchers: Lessons Learned
20185 citationsauthor #6
Closing the gaps in opioid use disorder research, policy and practice: conference proceedings
201810 citationsauthor #10
Cost of pharmacotherapy for opioid use disorders following inpatient detoxification.
201814 citationsauthor #8
Assessing The Impact Of State Policies For Prescription Drug Monitoring Programs On High-Risk Opioid Prescriptions.
201882 citationsauthor #6

TIMELINE

2001 64 citations

2002 182 citations

2003 0 citations

2004 722 citations

2005 262 citations

2006 1,676 citations

2007 210 citations

2008 447 citations

2009 397 citations

2010 485 citations

2011 153 citations

2012 650 citations

2013 492 citations

2014 227 citations

2015 444 citations

2016 440 citations

2017 287 citations

2018 796 citations

2019 551 citations

2020 411 citations

2021 205 citations

2022 161 citations

2023 86 citations

Unknown 0 citations

B. Schackman

PROFILE

PAPERS

TIMELINE

COAUTHOR MAP

CONCEPT FOOTPRINT